The other pedal

Read this site’s coverage of muscle and you get one lever, pulled hard: myostatin, the TGF-β brake, and the drugs racing to release it. That is a real and beautiful story — but it is only half the mechanism. Muscle mass is not set by a brake alone. It is set where a brake meets an accelerator, and the accelerator has a name of its own: IGF-1.

The two arms are genuinely opposed. The brake — myostatin and activin A through the Smad2/3 pathway — tells a fibre to hold back. The accelerator — growth hormone working through IGF-1, and IGF-1 working through Akt and mTOR — tells it to build. Where they balance is how much muscle you carry. This piece is the accelerator: the systemic signal, the local pulse a worked muscle writes for itself, the research peptides built to push it from outside, and the honest reason that pushing is harder and riskier than letting the brake off.

Growth hormone gets the headline, but it does surprisingly little of the growing itself. It travels to the liver and instructs it to make IGF-1, and IGF-1 is what actually reaches tissue and drives it to grow. Most of what we credit to GH is really IGF-1 carrying the message the last mile — the axis is a relay, not a broadcast.

At the muscle cell, IGF-1 binds its receptor tyrosine kinase and lights up the PI3K–Akt–mTOR pathway — the master switch for protein synthesis. Turn it up and the cell builds; it is the same pathway a heavy set and a protein-rich meal converge on. IGF-1 even has a quieter sibling, IGF-2, the dominant growth factor before birth and, curiously, the one the body built an entire receptor simply to clear away. But in adult muscle, IGF-1 is the accelerator that matters.

Systemic IGF-1 is a steady, whole-body tide. But muscle also makes IGF-1 locally, and it does something clever with it: when a fibre is mechanically loaded or damaged, it changes how it splices the IGF-1 gene, swapping in a different final exon. The product is the same IGF-1 core carried on a different C-terminal tail — the isoform called MGF, mechano growth factor.

What makes MGF interesting is that the distinct tail — its E-domain — appears to act on its own account, activating the satellite cells that repair and thicken a fibre, and it does so even in cells lacking the IGF-1 receptor. So it is not simply “local IGF-1” — it looks like a second message hidden in the same gene, one the muscle writes for itself in the moment it is worked. The catch, and it is a real one: the receptor for that E-domain has never been pinned down, and whether MGF is a genuinely distinct hormone is still argued. This is open biology, not settled fact.

If the accelerator is IGF-1, the obvious move is to add more of it. The problem is that native IGF-1 is almost never free: it circulates bound to IGF-binding proteins that buffer its activity and clear it within minutes. Inject plain IGF-1 and the binding proteins mop most of it up before it works. The research peptides in this corner are all, at heart, attempts to slip that leash.

• IGF-1 LR3 — the escape artist. Long R3 IGF-1 adds two changes to the sequence — an arginine swap at position 3 and a 13-residue N-terminal extension — that between them cripple binding-protein capture. It stays free, hits the receptor far more fully, and lasts hours instead of minutes, which is exactly why it is a standard cell-culture reagent.
• des(1-3)IGF-1 — the same idea, subtracted. Its sister analog reaches the same end by deletion, dropping the first three residues so the binding proteins lose their grip. Two routes, one goal: an IGF-1 the buffer can't hold.
• MGF / PEG-MGF — the local pulse, bottled. The synthetic MGF sold for research is the E-domain peptide itself. Native it lasts only minutes, so a pegylated form is offered to stretch it — an attempt to supply the mechano-pulse a muscle would otherwise have to earn under load.

It is elegant engineering, and it is the same trick the metabolic field used on GLP-1: the reach of a signal is set as much by what carries it as by what it says (more on that in two minutes to seven days). Free the peptide from its buffer and a two-minute signal becomes a multi-hour one.

Here is where the site’s creed — bullish on the science, sceptical on the page — has to earn its keep. The IGF-1 route is real, potent, and genuinely riskier than releasing the brake, for one structural reason: a growth signal is not muscle-specific.

• Unbuffered means unselective. The binding proteins that IGF-1 LR3 is built to dodge are not just a clearance nuisance — they are the body's way of rationing a mitogen. Sustained, systemic IGF-1-receptor activation is exactly the state epidemiology links to cancer risk. Strip the buffer everywhere and you push growth everywhere, not only in the worked muscle.
• The human muscle evidence is thin. For all the reagent-grade potency in a dish, controlled human data showing these peptides build or preserve functional muscle is sparse to absent. What exists is largely preclinical, and the headline claims run well ahead of it.
• Which is why the clinic chose the brake. The successful obesity-era programs don't push IGF-1 — they release myostatin, precisely because a targeted brake is easier to make safe than a systemic accelerator. The contrast is the lesson, not a footnote.

None of that makes the accelerator uninteresting — it makes it the harder, more beautiful engineering problem. The frontier worth watching is local: a signal like MGF that the muscle only issues where it is actually worked hints at a version of this pedal that could be pressed in one fibre without flooding the whole body. Get the aim right and the accelerator stops being the dangerous pedal. Until then, the honest read is that the brake is the lever the evidence supports, and the accelerator is the one the science is still learning to steer.